FindTrial
Sign In

Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study

Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030593
Enrollment
Unknown
Registered
2020-03-08
Start date
2020-03-10
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:None

Sponsors

The First Affiliated Hospital, College of Medicine of Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Aged >=18 years; (2) novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (trial version sixth) is diagnosed as new type coronavirus pneumonia common, heavy and critical patients; (3) Patients who used antiviral drugs such as lopinavir / ritonavir, abidol, darunavir / corbistadine and fabiravir for more than 72 hours.

Exclusion criteria

Exclusion criteria: (1) Patients allergic to antiviral drugs; (2) Pregnant or lactating women; (3) Patients whose GPT or total bilirubin is higher than the upper limit of normal value before antiviral drug use.

Design outcomes

Primary

MeasureTime frame
ALT;—

Countries

China

Contacts

Public ContactXiaoyang Lu

The First Affiliated Hospital, College of Medicine of Zhejiang University

luxiaoyang@zju.edu.cn+86 13605715886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026